



Press Release

Alkmaar, March 24, 2025

Cyclotron Noordwest and CircumSPECT Sign Exclusive Licensing Agreement for PET tracer [18F]-PSMA-JK-7 in the Netherlands

Cyclotron Noordwest B.V. (Cyclotron Noordwest) and CircumSPECT Diagnostic and Services GmbH (CircumSPECT) are pleased to announce that as of March 21, 2025, they have signed an exclusive licensing agreement for the application of PET tracer [18F]-PSMA-JK-7 in the Netherlands.

This collaboration marks an important step towards making this PET tracer accessible to a broader group of prostate cancer patients. Parties will combine their expertise and resources to accelerate the registration and introduction of [18F]-PSMA-JK-7 in the Netherlands.

[18F]-PSMA-JK-7 has demonstrated its value in the Netherlands in recent years on a named patient basis for diagnosis of metastatic prostate cancer. Cyclotron Noordwest will file for the registration of [18F]-PSMA-JK-7 with authorities later in 2025. Registration is currently expected to be finalized in second half of 2026.

About Cyclotron Noordwest

Cyclotron Noordwest, based in Alkmaar the Netherlands, is a leading supplier of radiopharmaceuticals in the Netherlands with a proven track record in the development and nationwide distribution of innovative PET tracers.

About CircumSPECT

CircumSPECT Diagnostics and Services GmbH, based in Bad Schönborn Germany, has been focusing since 2016 on innovative PSMA-Tracers, leading the research work carried by Prof. Bernd Neumaier to the development of a new 18F-PSMA Tracer. CircumSPECT is nowadays exclusive global licensee of this molecule with two patents granted in Europe and USA. In 2021 the Italian company ITEL telecomunicazioni srl became second shareholder.

End of Press Release